Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le...
-
The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
-
Austin, TX, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “T-Cell Engagers Market Size, Trends and Insights By Product Type (BiTEs...
-
EOM Pharmaceutical Holdings Report Promising Preclinical Results and Provides an Update on EOM613 and EOM147
-
Oxford, UK and Boston, MA – January 6, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in...
-
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
-
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA® (inebilizumab-cdon) for the...
-
InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
-
Oxford, UK and Boston, MA – November 13, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...
-
$32 million new equity injection adds to previously announced $59 millionNew investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3...